Skip to content

Evaluation of the efficacy of corticosteroids in septic arthritis in adults: Randomized double-blind controlled trial [CORSAR]

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-522193-37-00
Enrollment
200
Registered
2026-02-10
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic arthritis

Brief summary

Functional assessment score at week 24. This outcome will be assessed using the total WOMAC score (Western Ontario and McMaster Universities Osteoarthritis Index) for lower limb involvement (hip, knee, or ankle joints). For upper limb involvement (shoulder, elbow, or wrist joints), the QuickDASH score (Disabilities of the Arm, Shoulder and Hand) will be used. The WOMAC or QuickDASH score will be standardized and reported on a scale ranging from 0 to 100 points.

Detailed description

Joint flexion and extension measured at weeks 1, 6, and 24 using a goniometer. Presence of flexion contracture (defined as incomplete extension) at 3 months, assessed only for septic arthritis of the hip and knee., Any complication assessed by radiological examination of the joint at week 24., Number of surgical interventions between randomization and week 24., Duration of antibiotic therapy., Length of hospital stay, Pain assessed by Visual Analog Scale (VAS) at weeks 1, 6, and 24., Overall mortality., Biological inflammatory markers measured at weeks 1, 6, and 24., Patient self-assessment of recovery on a 0 to 5 scale (0 = no improvement, 5 = full recovery) at weeks 1, 6, and 24., Quality of life assessed by the EQ-5D-5L questionnaire at week 24., Number of days on painkillers, overall and according to WHO level (I, II, III), between W1 and W6, All adverse effects and side effects, particularly glycemic control and neuropsychiatric effects, monitored through patient self-surveillance.

Interventions

DRUGPlacebo de PREDNISONE ARROW 20 mg
DRUGcomprimé sécable

Sponsors

Assistance Publique Hopitaux De Paris
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Functional assessment score at week 24. This outcome will be assessed using the total WOMAC score (Western Ontario and McMaster Universities Osteoarthritis Index) for lower limb involvement (hip, knee, or ankle joints). For upper limb involvement (shoulder, elbow, or wrist joints), the QuickDASH score (Disabilities of the Arm, Shoulder and Hand) will be used. The WOMAC or QuickDASH score will be standardized and reported on a scale ranging from 0 to 100 points.

Secondary

MeasureTime frame
Joint flexion and extension measured at weeks 1, 6, and 24 using a goniometer. Presence of flexion contracture (defined as incomplete extension) at 3 months, assessed only for septic arthritis of the hip and knee., Any complication assessed by radiological examination of the joint at week 24., Number of surgical interventions between randomization and week 24., Duration of antibiotic therapy., Length of hospital stay, Pain assessed by Visual Analog Scale (VAS) at weeks 1, 6, and 24., Overall mortality., Biological inflammatory markers measured at weeks 1, 6, and 24., Patient self-assessment of recovery on a 0 to 5 scale (0 = no improvement, 5 = full recovery) at weeks 1, 6, and 24., Quality of life assessed by the EQ-5D-5L questionnaire at week 24., Number of days on painkillers, overall and according to WHO level (I, II, III), between W1 and W6, All adverse effects and side effects, particularly glycemic control and neuropsychiatric effects, monitored through patient self-surveillance

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 11, 2026